Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biqi Capsule is a proprietary Traditional Chinese Medicine (TCM) formulation developed and manufactured by Tianjin Darentang Group. It is widely used in China for the treatment of various musculoskeletal disorders, including rheumatoid arthritis, osteoarthritis, and soft tissue injuries. The formula consists of ten ingredients, with processed *Strychnos nux-vomica* as the principal component, supported by herbs such as *Astragalus membranaceus* and *Salvia miltiorrhiza*. Its pharmacological actions include anti-inflammatory, analgesic, and microcirculation-improving effects, primarily through the inhibition of pro-inflammatory cytokines like TNF-α and IL-6. Clinical studies have also highlighted its potential for bone protection and the reduction of bone marrow edema in joint diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biqi Capsule.